Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421299 · ClinicalTrials.gov registry record
A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 378
- Enrollment target
NCT05421299 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 378 participants.
The verdict
NCT05421299 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 378 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate overall survival (OS) for participants treated with abatacept versus those not treated with abatacept prior to hematopoietic stem cell transplantation (HSCT). Participants were included if their donors were unrelated and had 1-allele mismatched human leukocyte antigen (HLA) status.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2021-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05421299
The ClinicalTrials.gov registry entry for NCT05421299 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05421299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05421299 about?
NCT05421299 is a clinical study titled "A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate". The purpose of this study is to estimate overall survival (OS) for participants treated with abatacept versus those not treated with abatacept prior to hematopoietic stem cell transplantation (HSCT). Participants were included if their donors were unrelated and had 1-allele mismatched human leukocyt...
What is the current status of trial NCT05421299?
This trial is currently completed. The enrollment target is 378 participants. The study started on 2019-09-16. Estimated completion is 2021-02-15.
Who is sponsoring clinical trial NCT05421299?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.